Camurus (CAMX) Company presentation summary

Company overview and strategy

• Leader in opioid dependence treatment with established presence in Europe, Australia, and expanding in the US.

• Unique FluidCrystal technology platform validated commercially and licensed to Eli Lilly for long-acting incretins.

• Advancing a late-stage pipeline targeting endocrinology and rare diseases with blockbuster potential.

• Achieved rapid financial growth and sustainable profitability since 2022.

• Listed on Nasdaq Stockholm with over 290 employees.

Financial performance and guidance

• Revenues grew from SEK 601M in 2019 to SEK 1,868M in 2024, with 2025 guidance of SEK 2.3–2.6B (+23–39%).

• Profit before tax improved from negative SEK 362M in 2021 to SEK 553M in 2024, with 2025 guidance of SEK 0.9–1.2B (+63–117%).

• Strong cash position of ~SEK 3.5B and no debt.

Commercial execution and product portfolio

• Global leadership in long-acting opioid dependence treatment with Buvidal and Brixadi.

• Buvidal available in Europe, Australia, and MENA; Brixadi launched in the US with strong growth momentum.

• Oczyesa launched in Germany and approved in the EU/UK for acromegaly.

• Broad pipeline includes late-stage programs in acromegaly, GEP-NET, PLD, chronic pain, and metabolic diseases.